More precise treatment against leukemia
Technology
A novel RNA-targeting medicine against leukemia that is more precise than today’s options, resulting in less side effects. This is a clinically validated therapeutic target for several inflammatory diseases.
Market
Leukemia kills 300 000 to 400 000 people yearly. Today’s treatments are often aggressive and especially children and the elderly patients are in need for new alternative treatments.
Uniqueness
New unique drug candidates that are using RNA silencing technology are being developed and a solution for delivery will be explored.
Status
- Patent pending
- Seeking commercial partners and licensees
